MCG Nurse Consultant Diana Buck, RN, BSN, CNOR

Diana comes to MCG with 10 years of surgical experience…

SPRINGFIELD, Mo. (PRWEB)
February 27, 2020

Medical Consulting Group (MCG) welcomes Nurse Consultant Diana Buck, RN, BSN, CNOR, to its team of ambulatory surgery center (ASC) experts.

Diana comes to MCG with 10 years of surgical experience, six years within an ASC setting, and an extensive background in nurse management. She will serve MCG clients by guiding clinical directors towards licensure and accreditation and equipping them with the tools they need to successfully manage an ASC.

For more information about Diana and her team at Medical Consulting Group, visit MedCGroup.com or contact their main office at (417) 889-2040.

Medical Consulting Group, LLC

For more than 30 years, Medical Consulting Group has served practices, ASCs, and medical device manufacturers across the U.S. and Canada that are looking for customized business solutions and strategies. MCG’s services include practice and ASC consulting and development, as well as management of operations, revenue cycle, and clinical and regulatory compliance. They also specialize in multi-media marketing, digital and website services, and e-learning programs to help physicians and facilities learn to use and integrate technology. Learn more at MedCGroup.com.

Share article on social media or email:

“Dr. Adam Perzin has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson

PLEASANTON, Calif. (PRWEB)
February 26, 2020

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Adam Perzin, MD, New Jersey Urology in Mt. Laurel NJ, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Perzin has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“Dr. Adam Perzin has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit.

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504 nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

Providing high quality diabetes and mental health care via telemedicine at scale is necessary to help people with diabetes regardless of where they live, and we’re excited to use this approach to revolutionize diabetes and other chronic condition management.

MADRID (PRWEB)
February 26, 2020

Cecelia Health worked with The Jaeb Center for Health Research (JCHR) with support from The Helmsley Charitable Trust on a study that demonstrated successful remote continuous glucose monitor (CGM) initiation and sustained CGM use to improve diabetes outcomes and quality of life for people living with diabetes. This approach could substantially increase the adoption of CGM.

Despite the significant benefits of using CGM to help with diabetes management, many individuals with diabetes do not currently use a CGM device. Lack of access to trained diabetes care professionals and perceived complexity of CGM device onboarding and training are established barriers to wide adoption.

Results of the study showed that CGM could be successfully initiated remotely, without a clinic visit. Certified Diabetes Care & Education Specialists (CDCES) from Cecelia Health helped people living with type 1 and type 2 diabetes choose a CGM device, provided education to empower them to use the CGM and interpret its data, and to use that data to balance the use of insulin, exercise, and nutrition to better manage their diabetes and improve their quality of life. This study illustrates that adults with diabetes can be trained virtually to use CGM devices as an integral part of their diabetes self-management.

The 34 study participants had no CGM experience in the previous 24 months and were provided with a choice of using either Dexcom G6 or Abbott Freestyle Libre for the 12-week study. Results included a 100% persistence rate across the participants, who used the CGM throughout the study. A mean HbA1c reduction of 1.1 points (12%) was observed after 12 weeks. Additionally, participants experienced reduced diabetes distress, increased satisfaction with glucose monitoring, and fewer perceived technology barriers to CGM usage.

If widely implemented, a virtual clinic approach could substantially increase the adoption of CGM devices by people with diabetes and positively impact outcomes related to the condition.

“This study demonstrates that the right combination of technology and personalized coaching from expert clinicians is a highly effective way to manage diabetes and other chronic conditions,” stated Cecelia Health’s Chief Medical Officer, Dr. Arnold Saperstein, “Our goal is to use this study as a first step towards building a virtual diabetes and mental health clinic that can benefit people living with diabetes and our customers by driving down the cost of care.”

According to a 2020 study published by the CDC, 34.2 million Americans currently have diabetes and an additional 88 million (approximately 1 in 3) have pre-diabetes. A new case is diagnosed every 21 seconds, while the cost of diabetes reached $327 billion in 2017 and accounts for roughly 10% of annual U.S. healthcare expenditure. It has become an epidemic and it is showing no signs of slowing down.

Accordingly, the CGM market has seen exceptional growth over the past few years, with manufacturers such as Dexcom (NYSE: DXCM) and Abbott (NYSE: ABT) experiencing a surge in demand for CGM technology given the significant clinical benefits of such devices. Dexcom reported record 4Q19 sales of $463 million, an increase of 37% from last year, while Abbott Diabetes Care reported worldwide sales of $534 million, an increase of 58.5% from last year.

“I started Cecelia Health with a mission to educate and empower people living with diabetes to take control of managing their own condition” said Cecelia Health CEO and Founder, David Weingard. “Providing high quality diabetes and mental health care via telemedicine at scale is necessary to help people with diabetes regardless of where they live, and we’re excited to use this approach to revolutionize diabetes and other chronic condition management.”

Combining CGM technology with virtual access to highly qualified expert clinicians and mental health professionals builds the framework for a unique approach to virtual care that is geared toward improving the lives of people living with diabetes and other chronic diseases.

About Cecelia Health

Cecelia Health’s mission is to positively transform the lives of people living with diabetes and related chronic disease states. Cecelia Health’s Certified Diabetes Care & Education Specialist (CDCES) and other expert clinicians use Cecelia Health’s proprietary technology-enabled personalized coaching solution to optimize health outcomes at a low cost per patient and provide unique data-driven insights to health plans and ACOs seeking to improve quality measures, and pharmaceutical and medical device companies seeking to improve adherence. Cecelia Health has also engaged in numerous joint initiatives with the JDRF, American Diabetes Association, the Diabetes Research Institute, the Association of Diabetes Care & Education Specialists, and The Helmsley Charitable Trust.

Share article on social media or email:

Xtalks Life Science Webinars

TORONTO (PRWEB)
February 26, 2020

Join the live webinar on Tuesday, March 3, 2020 at 1pm EST with featured speaker Cristian Ionescu-Zanetti, PhD, Chief Technology Officer, Fluxion Biosciences as he provides an overview of ideal methods for sample processing.

The IsoFlux system is a bench-top solution for high-sensitivity circulating tumor cell (CTC) enrichment and recovery from blood samples, including samples collected in the BD Vacutainer® CPT™ Mononuclear Cell Preparation Tube. Based on Fluxion’s patented microfluidics, the IsoFlux System combines the power of antibody-based magnetic bead separations with the precision of flow cytometry. The IsoFlux System’s superior performance is proven daily in labs around the world, setting standards for CTC isolation efficiency, purity and ease of use.

• 
  Validated using thousands of samples across key solid tumor types, including lung, colorectal, breast, prostate, pancreatic, kidney, liver bladder, etc.
• Validated to recover CTCs even during early-stage disease

A key area of improvement has been improving pre-analytical IsoFlux protocol steps to reduce variability, eliminate the need for training skilled personnel, and reduce potential sample loss. Traditional Ficoll™ gradient processing methods require considerable skill and training. To help mitigate common blood sample handling challenges, we’ve turned to the BD Vacutainer® CPT™ Mononuclear Cell Preparation Tube, the only fully-closed system for peripheral blood mononuclear cell (PBMC) separation.

• BD Vacutainer® CPT™ Mononuclear Cell Preparation Tubes:
• Are ideal for operators of varying skill levels
• Decrease the number of sample transfer steps before CTC separation, reducing the possibility for cell loss as PBMC separation is carried out in the primary blood collection tube
• Provide a solution for fast pre-processing and cryopreservation of PBMCs / CTC samples before processing

The BD Vacutainer® CPT™ Mononuclear Cell Preparation Tube may be used in a variety of downstream applications commonly used in life science research. It has been used by customers in conjunction with technologies such as Flow Cytometry, ELISPOT, Cell Culture, CTC Isolation and Single Cell Genomics, allowing for fast and simple sample processing.

For more information or to register for this event, visit IsoFlux Rare Cell Separation: Streamline Workflows & Sample Transport With BD Vacutainer® CPT Mononuclear Cell Preparation Tubes.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

The new blog will help us engage our customers more effectively and showcase our experience, capabilities and success to prospects

WARMINSTER, Pa. (PRWEB)
February 26, 2020

Graphic Communications, Inc. (GCI), a full service custom pressure sensitive label and flexible packaging printer, has launched a company blog focused on industry trends, market sector news, company news, company case studies and service information highly pertinent to current and future customers.    

The industry topics include content on important business trends, new technologies, regulatory issues and other news that GCI’s customers will find valuable. The focus of the content will be food and beverage, health and beauty, medical and industrial market sectors and how labels can make such a huge difference.

Company news touch on GCI’s services, capabilities and case studies that highlight the success they have generated for customers in the market referenced above.

“The new blog will help us engage our customers more effectively and showcase our experience, capabilities and success to prospects,” according to the President, Loretta Andrews.

Please contact us at 1-800-441-5335 or visit the new blog at https://www.graphiccommunications.us/sticky-situations/

About Graphic Communications, Inc.

GCI is a family-owned and operated company established in 1974 and located in Warminster, PA. We understand the importance of your product arriving on time and on specification. That is why we have become a trusted “behind-the-scenes” partner to several companies within the printing industry—including our competitors. Built on a foundation of innovative processes, consistent quality and commitment to customer response and satisfaction, GCI has established its reputation as a fully integrated, single-source custom label printer for digital and flexographic labeling and packaging.

Share article on social media or email:

The addition of Health Advocate’s services enables plan participants to gain greater control over their healthcare purchases using Medcom’s tax-advantaged reimbursement plans, generating a win-win scenario for all participants.

JACKSONVILLE, Fla. (PRWEB)
February 25, 2020

Medcom Benefit Solutions announced this week a new partnership with Health Advocate, enabling its participants in pre-tax reimbursement programs to gain access to professional and proven support for navigating the complicated and expensive healthcare system.

About Medcom Benefit Solutions

Medcom Benefit Solutions administers a variety of tax-advantaged Consumer Driven Health Plans (CDHP) using sophisticated debit card technology to meet the convenience and needs of plan participants and the goals of the employer. With the addition of Health Advocate services, we can offer enhanced benefits designed to assist participants, spouses, children, parents, and parents-in-law, saving everyone time and money. These enhancements include answering tough FSA, HSA, and HRA questions, helping participants locate in-network providers, making appointments, resolving claims issues, managing provider fee negotiations, and much more.

President of Medcom, Michael J. Bracken, states, “As healthcare costs continue to increase, more employers are introducing high deductible health plans to their employees. The addition of Health Advocate’s services enables plan participants to gain greater control over their healthcare purchases using Medcom’s tax-advantaged reimbursement plans, generating a win-win scenario for all participants.”

Medcom is a leader in benefits administration and regulatory compliance, offering a diverse collection of products designed to help employers meet the challenges of a rapidly changing workforce.

About Health Advocate

Health Advocate makes healthcare easier for over 12,000 organizations and their employees and participants nationwide. Their services for Medcom clients include: clarification of benefits, providing answers to questions regarding participant FSA, HSA, or HRA accounts, locating in-network providers, assisting with appointment scheduling, researching medical claims, helping to resolve billing issues, and negotiating with providers on the participant’s behalf!

The newly developed partnership with Health Advocate means less stress, increased satisfaction, and a deeper knowledge of how FSA, HSA, and HRA benefits work for your clients and team members. Reach out to Medcom to learn more about your enrollment options.

Learn more about Medcom here: http://www.medcombenefits.com or call us (800) 523-7542

For more information, visit us at http://www.HealthAdvocate.com.

Share article on social media or email: